Velcade is a medicine that has Bortezomib as its active ingredient.
This medicine is an antineoplastic for injectable use, used in the treatment of tumors such as multiple myeloma.
Its action is to disrupt the cell's balancer mechanism, resulting in delayed tumor growth.
Velcade Indications
Treatment of multiple myeloma.
Velcade Side Effects
Weakness; Headache; insomnia; dizziness; anxiety; diarrhea; decreased hunger; constipation; lack of appetite; vomiting; indigestion; decreased blood platelets; anemia; swelling; Low pressure; joint pain; pains in the limbs; bone pain; muscle pain; back pain; difficulty breathing; cough, pneumonia; skin rash; itching; dehydration; blurred vision.
Contraindications of Velcade
Pregnancy risk D; women in the lactation phase; hypersensitivity to the product; children under 18 years of age.
Velcade Mode of Use
Injectable Use
Adults
- Treatment for 21 days : Inject 1.3 mg of Velcade intravenously, twice weekly for 2 weeks (on days 1, 4, 8 and 11). The procedure should be followed by a rest of 10 days.
- Treatment for 35 days : Inject 1.3 mg of Velcade intravenously once weekly for 4 weeks (on days 1, 8, 15 and 22). The procedure should be followed by a rest of 13 days.
Attention: The doses must be administered between a period of at least 72 hours between them.
